Related Experiment Video
Updated: Jun 17, 2026
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Screening for EGFR mutations in lung cancer
Miguel A Molina-Vila1, Jordi Bertran-Alamillo, Clara Mayo
1Medical Oncology Service, Pangaea Biotech, USP Institut Universitari Dexeus, Barcelona, Catalunya, Spain.
Abstract:
Certain mutations in the epidermal growth factor receptor (EGFR) gene confer hypersensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib in patients with advanced non-small cell lung cancer. Large-scale screening for EGFR mutations in such patients is feasible for predicting response to TKIs and thus guiding treatment.
Insights
Screening for epidermal growth factor receptor (EGFR) mutations predicts patient response to tyrosine kinase inhibitors (TKIs) like gefitinib and erlotinib. This approach is feasible for guiding treatment in advanced non-small cell lung cancer.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Advanced non-small cell lung cancer (NSCLC) treatment can be guided by molecular profiling.
- Epidermal growth factor receptor (EGFR) mutations are key drivers in a subset of NSCLC patients.
Purpose of the Study:
- To assess the feasibility of large-scale EGFR mutation screening in advanced NSCLC.
- To determine if EGFR mutation status predicts response to tyrosine kinase inhibitors (TKIs).
Main Methods:
- Analysis of EGFR gene mutations in patient samples.
- Correlation of mutation status with response to gefitinib and erlotinib therapy.
Main Results:
- Specific EGFR mutations were identified that confer sensitivity to gefitinib and erlotinib.
- Large-scale screening for these mutations is a practical approach.
Conclusions:
- EGFR mutation screening is a viable strategy for predicting TKI response in advanced NSCLC.
- This predictive approach can guide personalized treatment decisions for NSCLC patients.
